BioSpace News Archive

Allogene Therapeutics, Inc. announced its 2024 Platform Vision that redefines the future of CAR T by leveraging the unique attributes of allogeneic CAR T products.

Illumina, Inc. announced that it will issue results for the fourth quarter and full year 2023 following the close of market on Thursday, February 8, 2024.

Vaxcyte, Inc. announced an update regarding the ongoing progress of the Company’s pneumococcal conjugate vaccine franchise.

Fusion Pharmaceuticals Inc. announced significant progress with its FPI-2265 development program, an update on FPI-1434 Phase 1 Cohort 2 data and the production of the first clinical doses at the Company’s proprietary manufacturing facility.

Novocure announced the appointment of Nicolas Leupin, M.D., Ph.D., MBA to the role of Chief Medical Officer.

Acumen Pharmaceuticals, Inc. announced that management will present at the 42nd Annual J.P. Morgan Healthcare Conference taking place in San Francisco on Thursday, January 11, 2024, at 10:30 a.m. PT.

Allogene Therapeutics Inc. and Foresight Diagnostics announced a strategic partnership to develop a minimal residual disease in-vitro diagnostic to determine eligibility in ALPHA3, the first pivotal trial for first line consolidation treatment of large B-cell lymphoma.

BD, a leading global medical technology company, announced that it will report financial results for its first quarter of fiscal year 2024 on Thursday, February 1, 2024.

Nevro Corp. announced that members of its management team will participate in the 42nd Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2024.

Quince Therapeutics, Inc., a late-stage biotechnology company developing an innovative drug delivery technology that leverages a patient’s own biology to deliver rare disease therapeutics, announced that Dirk Thye, M.D., Quince’s Chief Executive Officer and Chief Medical Officer, will participate at two investor events taking place in San Francisco, California in January 2024.